Therapy Areas: Hereditary Disorders
Endo Ventures signs development and distribution contract with Quoin Pharmaceuticals
18 July 2022 -

Ireland-based Endo International plc (NASDAQ: ENDP) announced on Friday that its subsidiary Endo Ventures Limited has signed contract with Quoin Pharmaceuticals Inc. (NASDAQ: QNRX), an Israel-based specialty pharmaceutical company, for the development, registration, supply, commercialisation and distribution of Quoin's QRX003 on an exclusive basis in Canada.

QRX003 is Quoin's lead product for Netherton syndrome, a rare, hereditary disorder.

If QRX003 receives approval, Paladin Labs Inc., an Endo operating company, will handle all commercial activities in Canada. Presently, Paladin is expecting to introduce the product in Canada in 2025.

Login
Username:

Password:


Related Headlines

Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial

Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis

SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment

Alcresta Therapeutics' RELiZORB (iMMOBILIZED LIPASE) cartridge receives FDA expanded use clearance for paediatric patients aged 2 to 5 years

Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine

Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence

Vertex Pharmaceuticals receives European Commission approval for ORKAMBI (lumacaftor/ivacaftor) To treat children with cystic fibrosis aged 1 to <2 years old

cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial

Vertex Presents Data Demonstrating Significant Benefits of Long-Term Treatment with CFTR Modulators at the European Cystic Fibrosis Conference

First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant

Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study

Vertex Receives FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes

Aluna Raises USD 15.3m in Series B Funding

First Patient Dosed in Adaptive Phage Therapeutics' PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection